The Sample Processing and Immunoassay REsearch SPIRE Core (Core C) is designed to serve the RDRCC research community as a centralized resource for preparation and storage of clinically derived samples, for conducting a range of standard and innovative assays on clinically derived material and for serving as a conduit to other relevant research cores within the Institution. This core has facilitated, through disease-specific centers of excellence, the generation of large specimen bio-repositories recovered from well-pedigreed patient cohorts. In this manner, this well- established core, by providing biospecimen acquisition, processing, storage and retrieval services, has become a critical partner in enabling discovery at the translational interface, and in attracting the interest of a growing group of researchers. In addition, the high-quality assay services provided by Core C have resulted in numerous peer-reviewed publications, abstracts and investigator-initiated grant proposals. The assay capabilities in the Core play a critical role in pathway validation in human rheumatic disease cohorts.
The aims of this proposal are to sustain, grow and evolve this vital resource. We propose to expand the range of services offered to include innovative, cutting-edge technologies/approaches and serve as consultants and the pipeline to the necessary institutional expertise and resources that provide NextGen analytical approaches, and for advanced data analysis and interpretation. This interactive, dynamic framework has, and will continue to catalyze major leaps forward in research on the autoimmune rheumatic diseases. Core C will be directed by Drs. Casciola-Rosen and Soloski, both of whom have many years of experience in immunology, assay development, and directing high quality research responsive Cores. Drs. Andrade and Gutierrez, both of whom have many years of experience working with this Core team, will provide additional leadership. The close collaboration of this Core with the Administrative (Core A), Research Management and Patient Integrated Data (RAPID, Core B) and Data Science (Core D) Cores provides a powerful matrix to maximize synergies, resources and innovative collaborations in the environment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
1P30AR070254-01
Application #
9162942
Study Section
Special Emphasis Panel (ZAR1-YL (M1))
Project Start
2016-09-08
Project End
2021-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$459,785
Indirect Cost
$177,785
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Moseley, Kendall F; Naidoo, Jarushka; Bingham, Clifton O et al. (2018) Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer 6:104
Albayda, Jemima; Khan, Aamna; Casciola-Rosen, Livia et al. (2018) Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47:552-556
Wohlfahrt, Alyssa; Bingham 3rd, Clifton O; Marder, Wendy et al. (2018) Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS) Measures in RA Patients Starting or Switching a DMARD. Arthritis Care Res (Hoboken) :
Darrah, Erika; Giles, Jon T; Davis, Ryan L et al. (2018) Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. Front Immunol 9:2696
Leung, Ying Ying; Ogdie, Alexis; Orbai, Ana-Maria et al. (2018) Classification and Outcome Measures for Psoriatic Arthritis. Front Med (Lausanne) 5:246
Bartlett, S J; Gutierrez, A K; Butanis, A et al. (2018) Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Qual Life Res 27:2443-2451
Darrah, Erika; Yu, Fang; Cappelli, Laura C et al. (2018) Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol :
Albayda, Jemima; Bingham 3rd, Clifton O; Shah, Ami A et al. (2018) Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford) 57:760-762
Cappelli, Laura C; Konig, Maximilian F; Gelber, Allan C et al. (2018) Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. Arthritis Res Ther 20:59
Igusa, Takeru; Hummers, Laura K; Visvanathan, Kala et al. (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77:1179-1186

Showing the most recent 10 out of 22 publications